miR-193b Regulates Mcl-1 in Melanoma. 2011

Jiamin Chen, and Xiao Zhang, and Cindy Lentz, and Marie Abi-Daoud, and Geneviève C Paré, and Xiaolong Yang, and Harriet E Feilotter, and Victor A Tron
Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.

MicroRNAs play important roles in gene regulation, and their expression is frequently dysregulated in cancer cells. In a previous study, we reported that miR-193b represses cell proliferation and regulates cyclin D1 in melanoma cells, suggesting that miR-193b could act as a tumor suppressor. Herein, we demonstrate that miR-193b also down-regulates myeloid cell leukemia sequence 1 (Mcl-1) in melanoma cells. MicroRNA microarray profiling revealed that miR-193b is expressed at a significantly lower level in malignant melanoma than in benign nevi. Consistent with this, Mcl-1 is detected at a higher level in malignant melanoma than in benign nevi. In a survey of melanoma samples, the level of Mcl-1 is inversely correlated with the level of miR-193b. Overexpression of miR-193b in melanoma cells represses Mcl-1 expression. Previous studies showed that Mcl-1 knockdown cells are hypersensitive to ABT-737, a small-molecule inhibitor of Bcl-2, Bcl-X(L), and Bcl-w. Similarly, overexpression of miR-193b restores ABT-737 sensitivity to ABT-737-resistant cells. Furthermore, the effect of miR-193b on the expression of Mcl-1 seems to be mediated by direct interaction between miR-193b and seed and seedless pairing sequences in the 3' untranslated region of Mcl-1 mRNA. Thus, this study provides evidence that miR-193b directly regulates Mcl-1 and that down-regulation of miR-193b in vivo could be an early event in melanoma progression.

UI MeSH Term Description Entries
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D009596 Nitrophenols PHENOLS carrying nitro group substituents. Nitrophenol
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D006131 Growth Inhibitors Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth ( Cell Growth Inhibitor,Cell Growth Inhibitors,Growth Inhibitor,Growth Inhibitor, Cell,Growth Inhibitors, Cell,Inhibitor, Cell Growth,Inhibitor, Growth,Inhibitors, Cell Growth,Inhibitors, Growth
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000964 Antimetabolites, Antineoplastic Antimetabolites that are useful in cancer chemotherapy. Antineoplastic Antimetabolites
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D001713 Biphenyl Compounds Whitish aromatic crystalline organic compounds made up of two conjoined BENZENE rings. Compounds, Biphenyl
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide

Related Publications

Jiamin Chen, and Xiao Zhang, and Cindy Lentz, and Marie Abi-Daoud, and Geneviève C Paré, and Xiaolong Yang, and Harriet E Feilotter, and Victor A Tron
January 2015, BioMed research international,
Jiamin Chen, and Xiao Zhang, and Cindy Lentz, and Marie Abi-Daoud, and Geneviève C Paré, and Xiaolong Yang, and Harriet E Feilotter, and Victor A Tron
October 2023, Chinese medicine,
Jiamin Chen, and Xiao Zhang, and Cindy Lentz, and Marie Abi-Daoud, and Geneviève C Paré, and Xiaolong Yang, and Harriet E Feilotter, and Victor A Tron
August 2018, Oncotarget,
Jiamin Chen, and Xiao Zhang, and Cindy Lentz, and Marie Abi-Daoud, and Geneviève C Paré, and Xiaolong Yang, and Harriet E Feilotter, and Victor A Tron
September 2007, Oncogene,
Jiamin Chen, and Xiao Zhang, and Cindy Lentz, and Marie Abi-Daoud, and Geneviève C Paré, and Xiaolong Yang, and Harriet E Feilotter, and Victor A Tron
July 2016, Molecular medicine reports,
Jiamin Chen, and Xiao Zhang, and Cindy Lentz, and Marie Abi-Daoud, and Geneviève C Paré, and Xiaolong Yang, and Harriet E Feilotter, and Victor A Tron
October 2017, Scientific reports,
Jiamin Chen, and Xiao Zhang, and Cindy Lentz, and Marie Abi-Daoud, and Geneviève C Paré, and Xiaolong Yang, and Harriet E Feilotter, and Victor A Tron
June 2025, Cells,
Jiamin Chen, and Xiao Zhang, and Cindy Lentz, and Marie Abi-Daoud, and Geneviève C Paré, and Xiaolong Yang, and Harriet E Feilotter, and Victor A Tron
March 2019, Scientific reports,
Jiamin Chen, and Xiao Zhang, and Cindy Lentz, and Marie Abi-Daoud, and Geneviève C Paré, and Xiaolong Yang, and Harriet E Feilotter, and Victor A Tron
April 2015, FEBS letters,
Jiamin Chen, and Xiao Zhang, and Cindy Lentz, and Marie Abi-Daoud, and Geneviève C Paré, and Xiaolong Yang, and Harriet E Feilotter, and Victor A Tron
March 2021, Cells,
Copied contents to your clipboard!